Skip to main content

Advertisement

SpringerLink
Log in

Treatment of gastric carcinoids

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

Gastric carcinoid tumors are uncommon, but their percentage among all gastric malignancies has increased to 1.8%. Although they are most often discovered incidentally during endoscopy, gastric carcinoids can present with abdominal pain, bleeding, or symptoms related to the secretion of bioactive substances, most commonly histamine. Gastric carcinoids originate from the foregut and are derived from histamine-containing enterochromaffin-like (ECL) cells. Type I gastric carcinoid, the most common, exhibits slow growth and benign behavior. It occurs within the setting of chronic atrophic gastritis with achlorhydria-induced hypergastrinemia. Gastrin acts directly on ECL cells to induce hyperplasia, dysplasia, and, eventually, neoplasia. Type II gastric carcinoid, the least common type, occurs in patients with gastrinoma-associated multiple endocrine neoplasia syndrome-type 1 (MEN-1). The overall survival is related more to the underlying MEN-1 syndrome than to the gastric carcinoid. Rodents readily develop gastric carcinoid tumors in response to hypergastrinemia. However, in humans, other factors in addition to hypergastrinemia, such as pernicious anemia or MEN-1, must be present, implying that a genetic predisposition is necessary for the development of these tumors. Type III or sporadic gastric carcinoids exhibit a more malignant behavior, with overall 5-year survival rates of less than 50% and normal serum gastrin concentrations. Treatment of all types of gastric carcinoids is predicated upon accurate classification and staging. Radiolabeled somatostatin analogues are superior to conventional radiologic imaging techniques in detecting both primary and metastatic lesions. Treatment of choice for localized disease is excision, either endoscopically or surgically. Antrectomy, by eliminating the trophic effect of gastrin, can be useful for select type I carcinoids. Long-acting somatostatin analogues are excellent palliative agents.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Kidd M, Modlin IM, Mane SM, et al.: Q RT-PCR detection of chromogranin A: a new standard in the identification of neuroendocrine tumor disease. Ann Surg 2006, 243:273–280.

    Article  PubMed  Google Scholar 

  2. Oberndorfer S: Karzinoide tumoren des dunndarms [in German]. Frankf Z Pathol 1907, 1:237–240.

    Google Scholar 

  3. Godwin JD 2nd: Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975, 36:560–569.

    Article  PubMed  Google Scholar 

  4. Berge T, Linell F: Carcinoid tumours. Frequency in a defined population during a 12-year period. Acta Pathol Microbiol Scand 1976, 84:322–330.

    CAS  Google Scholar 

  5. Hodgson N, Koniaris LG, Livingstone AS, Franceschi D: Gastric carcinoids: a temporal increase with proton pump introduction. Surg Endosc 2005, 19:1610–1612.

    Article  PubMed  CAS  Google Scholar 

  6. Chen D, Zhao CM, Lindstrom E, et al.: Rat stomach ECL cells up-date of biology and physiology. Gen Pharmacol 1999, 32:413–422.

    Article  PubMed  CAS  Google Scholar 

  7. Conlon JM, Deacon CF, Richter G, et al.: Circulating tachykinins (substance P, neurokinin A, neuropeptide K) and the carcinoid flush. Scand J Gastroenterol 1987, 22:97–105.

    Article  PubMed  CAS  Google Scholar 

  8. Solcia E, Rinidi G, Silini E, et al.: Enterochromaffin-like (ECL) cells and their growths: relationship to gastrin, reduced acid secretion and gastritis. Baillieres Clin Gastroenterol 1993, 7:149–165.

    Article  PubMed  CAS  Google Scholar 

  9. Rindi G, Luinetti O, Cornaggia M, et al.: Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993, 104:994–1006.

    PubMed  CAS  Google Scholar 

  10. Manela FD, Ren J, Gao J, et al.: Calcitonin gene-related peptide modulates acid mediated somatostatin and gastrin release from rat antrum. Gastroenterology 1995, 109:701–706.

    Article  PubMed  CAS  Google Scholar 

  11. Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338–352.

    Google Scholar 

  12. Solcia E, Bordi C, Creutzfeld W, et al.: Histopathological classification of nonantral gastric endocrine growths in man. Digestion 1998, 41:185–200.

    Article  Google Scholar 

  13. Bordi C, Yu JY, Baggi MT, et al.: Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991, 67:663–672.

    Article  PubMed  CAS  Google Scholar 

  14. Borch K, Renyall H, Liedberg G, et al.: Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol 1986, 21:357–363.

    Article  PubMed  CAS  Google Scholar 

  15. Modlin IM, Lye KD, Kidd M: Carcinoid tumor of the stomach. Surg Oncol 2003, 12:153–172.

    Article  PubMed  Google Scholar 

  16. Rindi G, Bordi C, Rappel S, et al.: Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996, 20:168–172.

    Article  PubMed  CAS  Google Scholar 

  17. Schindl M, Kaserer K, Niederle B: Treatment of gastric neuroendocrine tumors-the necessity of a type-adapted treatment. Arch Surg 2001, 136:49–54.

    Article  PubMed  CAS  Google Scholar 

  18. Moesta KT, Schlag P: Proposal for a new carcinoid tumor staging system based on tumor tissue infiltration and primary metastasis: a prospective multicentre carcinoid tumor evaluation study. West German Surgical Oncologists’ Group. Eur J Surg Oncol 1990, 16:280–288.

    PubMed  CAS  Google Scholar 

  19. Bordi C, D’Adda T, Azzoni C, Ferraro G: Pathogenesis of ECL cell tumors in humans. Yale J Biol Med 1998, 71:273–284.

    PubMed  CAS  Google Scholar 

  20. Jensen RT: Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med 1998, 243:477–488.

    Article  PubMed  CAS  Google Scholar 

  21. Maggard MA, O’Connell JB, Ko CY: Updated population-based review of carcinoid tumors. Ann Surg 2004, 240:117–122.

    Article  PubMed  Google Scholar 

  22. Bordi C: Endocrine tumors of the stomach. Pathol Res Pract 1995, 191:373–380.

    PubMed  CAS  Google Scholar 

  23. Nobels FR, Kwekkeboom DJ, Coopmans W, et al.: Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997, 82:2622–2628.

    Article  PubMed  CAS  Google Scholar 

  24. Bordi C, Azzoni C, Feraro G, et al.: Sampling strategies for analysis of enterochromaffin-like cell changes in Zollinger-Ellison syndrome. Am J Clin Pathol 2000, 114:419–425.

    PubMed  CAS  Google Scholar 

  25. Giovannini M, Seitz JF, Thomas P, et al.: Endoscopic ultrasound examination using a curved-array transducer in benign and malignant diseases of the stomach. Results in 30 patients [in French]. Gastroenterol Clin Biol 1993, 17:26–32.

    PubMed  CAS  Google Scholar 

  26. Lindstrom E, Hakanson R: Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal. Regul Pept 2001, 97:169–180.

    Article  PubMed  CAS  Google Scholar 

  27. Modlin IM, Kidd M, Latich I, et al.: Current status of gastrointestinal carcinoids. Gastroenterology 2005, 128:1717–1751.

    Article  PubMed  Google Scholar 

  28. Lebtahi R, Le Cloirec J, Houzard C, et al.: Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy. J Nucl Med 2002, 43:889–895.

    PubMed  CAS  Google Scholar 

  29. Gibril F, Reynolds JC, Lubensky IA, et al.: Ability of somatostatin receptor scintigraphy to identify patients with gastric carcinoids: a prospective study. J Nucl Med 2000, 41:1646–1656.

    PubMed  CAS  Google Scholar 

  30. Zuetenhorst JM, Hoefnageli CA, Boot H, et al.: Evaluation of (111)In-pentetreotide, (131)I-MIBG and bone scintigraphy in the detection and clinical management of bone metastases in carcinoid disease. Nucl Med Commun 2002, 23:735–741.

    Article  PubMed  CAS  Google Scholar 

  31. Modlin IM, Lye KD, Kidd M: A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol 2004, 99:23–32.

    Article  PubMed  Google Scholar 

  32. Rappel S, Altendorfhofmann A, Stolte M: Prognosis of gastric carcinoid tumors. Digestion 1995, 56:455–462.

    PubMed  CAS  Google Scholar 

  33. Meko J, Norton J: Management of patients with Zollinger-Ellison syndrome. Ann Rev Med 1995, 46:395–411.

    Article  PubMed  CAS  Google Scholar 

  34. Modlin IM, Kidd M, Lye KD: Biology and management of gastric carcinoid tumors: a review. Eur J Surg 2002, 168:669–683.

    Article  PubMed  CAS  Google Scholar 

  35. Galligan CJ, Lawton GP, Tang LH, et al.: Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol 1995, 90:338–352.

    Google Scholar 

  36. Ichikawa J, Tanabe S, Koizumi W, et al.: Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy 2003, 35:203–206.

    Article  PubMed  CAS  Google Scholar 

  37. Hirschowitz BI, Griffith J, Pellegrin D, et al.: Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology 1992, 102:1409–1418.

    PubMed  CAS  Google Scholar 

  38. Modlin IM, Latich I, Kidd M, et al.: Therapeutic options for gastrointestinal carcinoids. Clin Gastroenterol Hepatol 2006, 4:526–547.

    Article  PubMed  CAS  Google Scholar 

  39. Welin SV, Janson ET, Sundin A, et al.: High-dose treatment with a long acting somatostatin analogue in patients with disseminated mid-gut carcinoid tumors. Eur J Endocrinol 2004, 151:107–112.

    Article  PubMed  CAS  Google Scholar 

  40. Arnold R, Trautmann ME, Creutzfeld W, et al.: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroenteropancreatic tumors. Gut 1996, 172:61–67.

    Google Scholar 

  41. Dirix LY, Vermeulen PB, Fierens H, et al.: Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors—an antiangiogenic effect? Anticancer Drugs 1996, 7:175–181.

    Article  PubMed  CAS  Google Scholar 

  42. Schally A: Oncological applications of somatostatin analogue. Cancer Res 1988, 48:6977–6985.

    PubMed  CAS  Google Scholar 

  43. Hillman N, Herranz L, Alverez C, et al.: Efficacy of octreotide in the regression of a metastatic carcinoid tumor despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998, 106:226–230.

    Article  PubMed  CAS  Google Scholar 

  44. Kvols LK, Moertel CG, O’Connell MJ, et al.: Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986, 315:663–666.

    Article  PubMed  CAS  Google Scholar 

  45. Oberg K: Treatment of neuroendocrine tumors. Cancer Treat Rev 1994, 20:331–355.

    Article  PubMed  CAS  Google Scholar 

  46. Oberg K: Future aspects of somatostatin-receptor-mediated therapy. Neuroendocrinology 2004, 80(Suppl 1):57–61.

    PubMed  Google Scholar 

  47. Frolich JC, Bloomgarden ZT, Oates JA, et al.: The carcinoid flush. Provocation by pentagastrin and inhibition by somatostatin. N Engl J Med 1978, 299:1055–1057.

    Article  PubMed  CAS  Google Scholar 

  48. Dharmsathaphorn K, Sherwin RS, Cataland S, et al.: Somatostatin inhibits diarrhea in the carcinoid syndrome. Ann Intern Med 1980, 92:68–69.

    PubMed  CAS  Google Scholar 

  49. Schnirer II, Yao JC, Ajani JA: Carcinoid—a comprehensive review. Acta Oncol 2003, 42:672–692.

    Article  PubMed  Google Scholar 

  50. Ahlman H, Kolby L, Lundell, et al.: Clinical management of gastric carcinoid tumors. Digestion 1994, 55Suppl 3):77–85.

    Article  PubMed  Google Scholar 

  51. Higam AD, Dimaline R, Varro A, et al.: Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998, 114:817–822.

    Article  Google Scholar 

  52. Dakin GF, Warner RR, Pomp A, et al.: Presentation, treatment, and outcome of type 1 gastric carcinoid tumors. J Surg Oncol 2006, 93:368–372.

    Article  PubMed  Google Scholar 

  53. Comaru-Schally AM, Schally AV: A clinical overview of carcinoid tumors: perspectives for improvement in treatment using peptide analogs (review). Int J Oncol 2005, 26:301–309.

    PubMed  CAS  Google Scholar 

  54. Kaltsas G, Rockall A, Papadogias D, et al.: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumors. Eur J Endocrinol 2004, 151:15–27.

    Article  PubMed  CAS  Google Scholar 

  55. Krenning EP, Kwekkeboom DJ, Valkema R, et al.: Peptide receptor radionuclide therapy. Ann N Y Acad Sci 2004, 1014:234–245.

    Article  PubMed  CAS  Google Scholar 

  56. Boerlin V, van der Hoek J, Beglinger Ch, et al.: New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003, 26(8 Suppl):14–16.

    PubMed  CAS  Google Scholar 

  57. Bruns C, Lewis I, Briner U, et al.: SOM230: a novel somatostatin peptidomimetic with broad somatostatin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002, 146:707–716.

    Article  PubMed  CAS  Google Scholar 

  58. Schmid HA, Schoeffter P: Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 2004, 80(Suppl 1):47–50.

    Article  PubMed  CAS  Google Scholar 

  59. Kvols L, Oberg K, de Herder W: Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR [abstract]. Proc Am Soc Clin Oncol 2005, 23:8024.

    Google Scholar 

  60. Yao JC, Chamsangavej C, Faria SC: Rapid decrease in blood flow (BF), blood volume (BV), and vascular permeability (PS) in carcinoid patients treated with bevacizumab. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:3013.

    Google Scholar 

  61. Carr K, Yao JC, Rashid A: A phase II trial of imatinib in patients with advanced carcinoid tumor. ASCO annual meeting proceedings (post-meeting edition) [abstract]. J Clin Oncol 2004, 22:4124.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, McGuire VAMC, 111N, 1201 Broad Rock Boulevard, Richmond, VA, 23249, USA

    Mitchell L. Schubert

Authors
  1. Wei Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell L. Schubert
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mitchell L. Schubert.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hou, W., Schubert, M.L. Treatment of gastric carcinoids. Curr Treat Options Gastro 10, 123–133 (2007). https://doi.org/10.1007/s11938-007-0064-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-007-0064-5

Keywords

Search

Navigation